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In this study, we have established the molecular basis of xeroderma pigmentosum (XP) in two unrelated Chinese
families. In the ﬁrst patient with consanguineous parents, we mapped the disease-causing locus XPC using single-
nucleotide polymorphism microarray. Mutational analysis of the XPC gene showed that the patient is homozygous
for a nonsense mutation, E149X. After developing DNA-based diagnosis of XPC, we screened another XP patient for
XPC mutations. We found that the second patient is a compound heterozygote of 1209delG and Q554X in this gene.
These are the ﬁrst XPC-causing mutations identiﬁed in Chinese patients.
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To date, eight different disease-causing genes have been
identified in xeroderma pigmentosum (XP) patients: seven
involve defective nucleotide excision repair (NER) (XPA-
XPG), and one, the XP variant, results in replication of dam-
aged DNA on the leading strand (Cleaver, 2000; Moriwaki
and Kraemer, 2001). According to the National Center for
Biotechnology Information (NCBI) Build 34 human genome
map, XPA is located on chromosome 9q22.33, XPB
(ERCC3) is located on chromosome 2q14.3, XPC is locat-
ed on chromosome 3p25.1, XPD (ERCC2) is located on
chromosome 19q13.32, XPE (DDB2) is located on chromo-
some 11p11.2, XPF (ERCC4) is located on chromosome
16p13.12, XPG (ERCC5) is located on chromosome
13q33.1, and XPV (pol eta) is located on chromosome
6p21.1. In sum, eight of 22 autosomes have XP genes, and
traditionally these XP subgroups have been determined
by complementation assay. In Chinese populations, the
complementation group assignment of XP patients has
been limited (Kraemer et al, 1987). We report here on the
molecular investigations of two Chinese families with XP.
Results
Using the whole-genome scan, we reduced the number of
possible disease-causing XP loci in the first patient from
eight to three, namely, XPC, XPF, and XPV (Table I). We next
ranked the quality of the three homozygous chromosomal
regions as follows: (1) the size of the homozygous chromo-
somal region (normalized with the size of the respective
chromosome); (2) the number of single-nucleotide poly-
morphisms (SNP) in the homozygous chromosomal region;
and (3) the number of SNP on the centromeric and telomeric
side of the XP locus in the homozygous chromosomal re-
gion. The best of each was scored as 3 and the worst was
scored as 1. A high-quality homozygous chromosomal re-
gion should have the largest size, the highest number of
SNP, and an equal number of SNP on both sides of the XP
locus. The XP locus with the highest total score was se-
lected for mutation screening.
Among the three loci, the XPC locus had the highest
score (Table II). Therefore, we screened for the mutations of
the XPC gene first. With direct DNA sequencing, the patient
was found to be homozygous for a 445G4T mutation in
exon 4, changing codon 149 from GAA to a premature stop
codon TAA, i.e., E149X (Fig 1). The parents and the three
sisters of the proband were all heterozygous for E149X. Af-
ter developing DNA-based diagnosis of XPC for patient 1,
we screened patient 2 for XPC mutations. In patient 2, two
novel mutations were identified in exon 9. The first mutation
is 1659C4T, changing codon 554 from CAG to a premature
stop codon, TAG, i.e., Q554X (Fig 1). The second mutation
is 1209delG causing a frameshift of the reading frame
(Fig 1), and creating a premature stop codon downstream at
codon 525. The mother was heterozygous for 1659C4T,
whereas the father was heterozygous for 1209delG (data
not shown).
Discussion
Of the 23 reported XPC families, most of the XPC mutations
result in premature termination of the XPC protein (LegerskiAbbreviations: HuSNP, human SNP; XP, xeroderma pigmentosum
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and Peterson, 1992; Li et al, 1993; Khan et al, 1998; Cleaver
et al, 1999; Chavanne et al, 2000; Slor et al, 2000; Gozukara
et al, 2001; Khan et al, 2004), either because of nonsense or
frameshift mutations. We present here the molecular de-
tection and analysis of three novel XPC mutations, E149X,
Q554X, and 1209delG, in a Chinese population. These mu-
tations might be ethnic-specific mutations as they have not
been reported in other populations.
Although fibroblast cell lines of the two patients are not
available for cell-based assays, nonsense or frameshift XPC
mutations downstream of R149X, 1209delG, and Q554X
have been fully characterized in previous studies and have
shown defective NER activity (Li et al, 1993; Chavanne et al,
2000). Of these, 10 fully characterized nonsense or frame-
shift XPC mutations are located downstream of R149X and
three fully characterized nonsense or frameshift mutations
are located downstream of 1209delG and Q554X (http://
xpmutations.org). Therefore, we predict that XPC cell lines
having R149X, 1209delG, and Q554X will also have defects
of NER and that these mutations are responsible for causing
disease in our patients.
The mapping study was essential in preparing the ground
for the mutation study and decreasing the burden of a
complete sequencing of all possible loci for this disease.
The results of the mapping study and the mutation study
were consistent, validating this approach. We were able to
prioritize the XPC loci for mutational analysis in the first
patient based on the history of consanguinity, by performing
a whole-genome scan for homozygous chromosomal re-
gions, using SNP microarrays. Consanguinity of parents is
common in patients with rare autosomal recessive diseases
and has been reported in about 30% of the XP cases
(Kraemer et al, 1987). In one study of XPC, 10 of 13 patients
were homozygous for the mutated XPC alleles (Chavanne
et al, 2000). The human SNP (HuSNP) genotyping assay is
fully automated, and this parallel assay can be completed in
2 d. With future reductions in the cost of SNP genotyping,
whole-genome scans should become more widely availa-




Family 1 The patient was an ethnic Chinese girl from southern
China, whose parents were blood relatives (fifth degree). She was
normal at birth, but at a very young age, many freckles were noted
over her face, and her skin was rough and dry. The patient’s elder
brother had similar skin problems. Believing their daughter’s skin
problems were not serious, her parents failed to seek medical ad-
vice or to adopt stringent sun-protective measures. Similar to her
peers, the patient attended public school with an average aca-
demic performance. In adolescence, the patient and her elder
brother started to develop numerous non-melanoma skin cancers,
mainly over their faces that were treated with multiple local exci-
sions. The patient was referred to us at the age of 28 y for man-
agement of incessant skin cancers. By then, she had already had
multiple excisions over her face and nose. Because of the muti-
lating nature of her surgeries, prosthesis was required to cover the
nasal defect. In a therapeutic trial, she was put on systemic retinoid
etretinate and, later, acitretin at a dose of 0.5 mg per kg per d. This
was, however, discontinued after 2 y as new skin tumors continued







3 WIAF-4560 AA 3p26.3 0.33
WIAF-685 AA 3p26.2 12.19
WIAF-1793 BB 3p26.1 16.52
WIAF-3235 BB 3p25.3 26.21
WIAF-3008 BB 3p25.3 27.30
WIAF-838 AA 3p25.3 29.01
WIAF-2563 BB 3p25.2 32.79
XPC 3p25.1 40.05
WIAF-3865 AA 3p24.3 41.25
WIAF-906 AA 3p24.3 41.25
WIAF-1946 BB 3p24.2 47.84
WIAF-1765 BB 3p24.1 49.81
WIAF-721 AA 3p24.1 50.81
WIAF-3380 BB 3p23 52.55
WIAF-1789 BB 3p22.3 55.74
WIAF-741 BB 3p22.3 55.77
6 WIAF-2103 AA 6p21.2 50.16
WIAF-2810 AA 6p21.1 59.61
XPV 6p21.1 66.47
WIAF-538 AA 6p21.1 73.50
WIAF-3166 BB 6p12.3 77.33
WIAF-3444 BB 6p12.3 79.93
WIAF-3784 BB 6p12.1 80.63
WIAF-4584 AA 6p12.1 81.85
WIAF-1670 BB 6q12.2 83.85
WIAF-3700 BB 6q12 86.29
WIAF-2690 AA 6q14.1 88.01
16 WIAF-506 BB 16p13.3 6.76
WIAF-627 AA 16p13.3 7.01
WIAF-924 BB 16p13.2 11.65
WIAF-3828 BB 16p13.2 15.36
WIAF-3324 AA 16p13.2 15.51
XPF 16p13.12 28.30
WIAF-2652 AA 16p12.3 37.48
WIAF-1870 BB 16p12.1 44.43
WIAF-2136 AA 16p12.1 56.86
AA, homozygous for the A marker; BB, homozygous for the B marker.
We excluded chromosomal regions with XP loci marked by less than five
homozygous SNP or with a size less than the median marker gap size 1.2
cM, because these regions provided insufficient data to determine ho-
mozygosity.
SNP, single-nucleotide polymorphisms; HuSNP, human SNP; XP,
xeroderma pigmentosum.
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Figure 1
Upper half: electropherograms of exon 4 of the XPC gene of patient 1 with homozygous 445G4T (top panel) and her father with heterozygous
445G4T (bottom panel). Lower half: electropherograms of exon 9 of the XPC gene of patient 2 with heterozygous 1659C4T (top panel) and
heterozygous 1209delG (bottom panel). The 1 bp deletion, 1209delG, causes a doubly heterozygous pattern: from 50-CCTCCAGCGAGGAA-
GATGAGGGCCCAGGAGACAAGCAGGAGAAG-30 to 50-CCTCCAGCGAGGAAGATGA(G/G)(G/G)(G/C)(C/C)(C/C)(C/A)(A/G)(G/G)(G/A)(A/G)(G/A)(A/
C)(C/A)(A/A)(A/G)(G/C)(C/A)(A/G)(G/G)(G/A)(A/G)(G/A)(A/A)(A/G)-30. The sequences are shown in the sense direction. A heterozygous site is denot-
ed by the letter N. Polymerase chain reaction (PCR): The genomic sequence of the human XPC gene was obtained from the NCBI human genome
sequence database. All the exons and intron–exon boundaries of the XPC gene were amplified by PCR. The primer sequences and the PCR
conditions are available on the Journal website (http://www.jidonline.org) as supplementary material. Mutational analysis: The PCR products were
purified by Microspin S-300 HR columns (GE Healthcare, Uppsala, Sweden), and both strands were sequenced using the amplification primers as
sequencing primers and BigDyeDeoxy terminator cycle sequencing reagents according to the manufacturer’s instructions (Applied Biosystems,
Foster City, California). Products of the sequencing reactions were purified by Centri-Sep spin columns (Princeton Separations, Adelphia, New
Jersey). Purified sequencing fragments were separated by capillary electrophoresis and detected via laser-induced fluorescence on an ABI Prism
3100 genetic analyzer (Applied Biosystems).
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to develop. Her elder brother died, at the age of 32 y, of dissem-
inated skin cancers; whereas our patient died at the age of 37 y, 2 y
after she was diagnosed to have inoperable clear cell carcinoma of
the ovary. Up to their death, no neurological deficits were noted.
Family 2 The patient was born to parents who were clinically nor-
mal ethnic Chinese with no consanguinity. They had one daughter
and one son; both were affected. Their daughter was born in 1976
and was healthy at birth. She had dry skin and developed freckles
over the sun-exposed areas in early childhood. The patient at-
tended normal school and had distinguishing academic perform-
ance. All along, she was under the care of a physician with the
clinical diagnosis of XP. Though repeatedly advised on sunlight
avoidance, both parents and the patient underestimated the dam-
aging effect of sun exposure and failed to adhere to stringent
sunlight protective measures. At the age of 8 y, she developed the
first skin tumor at the tip of the nose. Thereafter, multiple skin
tumors including basal cell carcinoma and squamous cell carci-
noma developed over her face, nose, and scalp. She had been put
on topical 5-flurouracil (Efudix, ICN Pharmaceuticals, Costa Mesa,
California), tretinoin and flurocytocine cream without success. Lat-
er, surgical excision and cryotherapy became routine procedures
for her skin tumors. In 1988, at the age of 12 y, she was put on low-
dose etretinate at 10 mg per d. Unfortunately, multiple skin tumors
continued to come up over her face, nose, eyelid, and forehead.
She finally died of disseminated carcinoma at the age of 21 y.
Her little brother was born in 1982. Multiple freckles were noted
over the sun-exposed areas since early childhood. Having a bitter
experience with their first child, the parents this time adopted vig-
orous measures to protect their second child. Long-sleeve shirt,
broad beam hat, and high SPF (50) sunscreen were used. Over the
years, only actinic keratosis developed over the patient’s face and
no skin tumor has ever been documented. The patient was also put
on etretinate 20 mg daily at the age of 8 y and has continued with
it since then. The patient had a normal academic performance
and enjoyed his social life. No neurological deficit has been de-
tected so far.
DNA extraction Genomic DNA of the patients, parents, and sib-
lings was extracted from peripheral blood samples with a QIAamp
blood kit (Qiagen, Hilden, Germany), according to the manufac-
turer’s instruction. Participants gave their written informed consent.
The medical ethical committee of the Chinese University of Hong
Kong approved all described studies. The study was conducted
according to Declaration of Helsinki Principles.
HuSNP probe array and HuSNP mapping assay In patient 1, we
examined the homozygosity of SNP flanking all the known XP loci
using a whole-genome scan by Affymetrix HuSNP probe arrays
(Santa Clara, California). Because the parents are consanguineous,
the disease-causing XP locus of patient 1 should fall in a chromo-
somal region marked by homozygous SNP, because the two dis-
ease-causing chromosomal regions, one from each parents, are
identical-by-descent. SNP genotyping was performed according
to the HuSNP protocol supplied by Affymetrix. HuSNP probe ar-
rays are manufactured using technology that combines photolith-
ographic methods and combinatorial chemistry. Tens to hundreds
of thousands of different oligonucleotide probes are synthesized
in a 0.81 cm  0.81 cm area on each HuSNP probe array. With a
median marker gap size of 1.2 cM, 1308 fully mapped markers are
evenly distributed across the human genome (Fan et al, 2000).
Briefly, starting with 120 ng of genomic DNA, a set of 24 si-
multaneously run multiplex PCR amplify the HuSNP represented in
the GeneChip HuSNP mapping assay. The amplified SNP are fur-
ther amplified and concomitantly labeled using biotinylated primers
in a second set of 24 simultaneously run labeling PCR. The bio-
tinylated PCR products are then pooled, concentrated, and pre-
pared for hybridization. The biotinylated amplification products,
which reflect the bi-allelic genotype (typed as A or B) in the sample
DNA, are hybridized to the GeneChip HuSNP probe arrays during
an overnight incubation at 441C in the GeneChip hybridization ov-
en. On the next day, the probe arrays are thoroughly washed and
stained with a complex of streptavidin–phycoerythrin and biotiny-
lated anti-streptavidin immunoglobulin G antibody. The automated
wash and stain procedures are run on the GeneChip fluidics station
400, under the control of Affymetrix microarray suite software 5.0.
The stained probe arrays are scanned in an Agilent GeneArray
scanner, also under the control of Affymetrix microarray suite soft-
ware 5.0. Each probe array is scanned twice to capture the light
emitted at wavelengths of 530 and 570 nm, generating two scan
image files. The Affymetrix microarray suite software 5.0 processes
the two scan images to calculate the signal intensities on the probe
array. Genotype calling is performed by Genotype Viewer 1.0
(Affymetrix).
The work described in this paper was partially supported by a grant
from the Research Grants Council of the Hong Kong Special Admin-
istrative Region, China (Project no. CUHK4472/03M).
Supplementary Material
The following material are available from http://www.blackwellpublishing.
com/products/journals/suppmat/JID/JID23563/JID23563sm.htm
Table S1. Primes for amplification of the coding exons of the XPC gene
DOI: 10.1111/j.0022-202X.2004.23563.x
Manuscript received June 7, 2004; revised August 30, 2004; accepted
for publication September 2, 2004
Address correspondence to: Ching-Wan Lam, Department of Chemical
Pathology, The Chinese University of Hong Kong, Prince of Wales
Hospital, Hong Kong, China. Email: ching-wanlam@cuhk.edu.hk
References
Chavanne F, Broughton BC, Pietra D, et al: Mutations in the XPC gene in families
with xeroderma pigmentosum and consequences at the cell, protein and
transcript levels. Cancer Res 60:1974–1982, 2000
Cleaver JE: Common pathways for ultraviolet skin carcinogenesis in the repair
and replication defective groups of xeroderma pigmentosum. J Dermatol
Sci 23:1–11, 2000









No. of SNP in
the homozygous
chromosomal region
No. of SNP on the
centromeric and telomeric
sides of the XP gene
Total
score
XPC 55.4 0.24 15 8,7 8
XPF 50.1 0.37 8 3,5 6
XPV 37.9 0.21 10 8,2 4
SNP, single-nucleotide polymorphisms; XP, xeroderma pigmentosum.
90 LAM ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
Cleaver JE, Thompson LH, Richardson AS, States JC: A summary of mutations in
the UV-sensitive disorders: Xeroderma pigmentosum, cockayne syn-
drome, and trichothiodystrophy. Hum Mutat 14:9–22, 1999
Fan JB, Chen X, Halushka MK, et al: Parallel genotyping of human SNPs using
generic high-density oligonucleotide tag arrays. Genome Res 10:853–860,
2000
Gozukara EM, Khan SG, Metin A, et al: A stop codon in xeroderma pigmentosum
group C families in Turkey and Italy: Molecular genetic evidence for a
common ancestor. J Invest Dermatol 117:197–204, 2001
Khan SG, Levy HL, Legerski R, et al: Xeroderma pigmentosum group C splice
mutation associated with autism and hypoglycinemia. J Invest Dermatol
111:791–796, 1998
Khan SG, Metin A, Gozukara E, et al: Two essential splice lariat branchpoint
sequences in one intron in a xeroderma pigmentosum DNA repair gene:
Mutations result in reduced XPC mRNA levels that correlate with cancer
risk. Hum Mol Gene 13:343–352, 2004
Kraemer KH, Lee MM, Scotto J: Xeroderma pigmentosum. Cutaneous, ocular,
and neurologic abnormalities in 830 published cases. Arch Dermatol
123:241–250, 1987
Legerski R, Peterson C: Expression cloning of a human DNA repair gene involved
in xeroderma pigmentosum group C. Nature 359:70–73, 1992
Li L, Bales ES, Peterson CA, Legerski RJ: Characterization of molecular defects
in xeroderma pigmentosum group C. Nat Genet 5:423–427, 1993
Moriwaki S, Kraemer KH: Xeroderma pigmentosum—bridging a gap between clinic
and laboratory. Photodermatol Photoimmunol Photomed 17:47–54, 2001
Slor H, Batko S, Khan SG, et al: Clinical, cellular, and molecular features of an Israeli
xeroderma pigmentosum family with a frameshift mutation in the XPC
gene: Sun protection prolongs life. J Invest Dermatol 115:974–980, 2000
DIAGNOSIS OF XPC BY SNP MICROARRAY 91124 : 1 JANUARY 2005
